November 13, 2026
Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







